RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.63
+5.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 54.9M | 74.7M | 58.8M | 43.9M | 39.7M |
| Cost of Revenue | 80.5M | 121.0M | 45.2M | 42.6M | 48.3M |
| Gross Profit | (25.6M) | (46.3M) | 13.6M | 1.3M | (8.6M) |
| Operating Expenses | |||||
| R&D Expense | 381.9M | 425.3M | 314.4M | 241.2M | 155.7M |
| SG&A Expense | 151.4M | 176.6M | 178.2M | 110.8M | 81.6M |
| General & Admin Expense | 151.4M | 176.6M | 178.2M | 110.8M | 81.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (14.9M) | — | — | (699.0K) | (162.0K) |
| Total Operating Expenses | 518.4M | 601.9M | 492.6M | 351.3M | 237.1M |
| Cost and Expenses | 598.9M | 722.8M | 537.8M | 393.9M | 285.4M |
| Operating Income (EBIT) | (544.0M) | (648.1M) | (479.0M) | (350.1M) | (245.7M) |
| Non-Operating | |||||
| Interest Income | 23.1M | 22.8M | 15.8M | 19.1M | 6.3M |
| Interest Expense | 1.5M | 1.8M | 1.6M | 97.0K | 55.0K |
| Net Interest Income | 21.6M | 21.0M | 14.2M | 19.0M | 6.2M |
| Other Non-Op Income/Expense | 20.5M | 3.2M | 14.2M | 17.9M | 6.3M |
| Non-Operating Income (excl Interest) | (21.2M) | (5.0M) | (15.8M) | (18.0M) | (6.3M) |
| EBT (Pre-Tax Income) | (523.5M) | (644.9M) | (464.8M) | (332.1M) | (239.5M) |
| Income Tax Expense | (4.6M) | (136.0K) | (1.1M) | (4.1M) | — |
| Bottom Line | |||||
| Net Income | (518.9M) | (644.8M) | (463.7M) | (328.1M) | (239.5M) |
| Earnings from Cont. Ops | (518.9M) | (644.8M) | (463.7M) | (328.1M) | (239.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (518.9M) | (644.8M) | (463.7M) | (328.1M) | (239.5M) |
| Per Share | |||||
| Basic EPS | ($1.04) | ($1.44) | ($1.69) | ($1.58) | ($1.36) |
| Diluted EPS | ($1.04) | ($1.44) | ($1.69) | ($1.58) | ($1.36) |
| Revenue Per Share | $0.10 | $0.17 | $0.21 | $0.21 | $0.23 |
| Shares | |||||
| Basic Shares Outstanding | 532.5M | 447.4M | 274.2M | 207.9M | 175.5M |
| Diluted Shares Outstanding | 532.5M | 447.4M | 274.2M | 207.9M | 175.5M |
| Profitability Metrics | |||||
| EBITDA | (444.4M) | (559.4M) | (426.7M) | (307.6M) | (227.7M) |
| D&A | 78.4M | 83.7M | 36.5M | 24.4M | 11.8M |
| EBIT | (522.8M) | (643.1M) | (463.2M) | (332.0M) | (239.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026